Speaker Profile
Ph.D., Founder, CTO, Cofactor Genomics
Biography
Jarret Glasscock is a geneticist and computational biologist. Prior to co-founding Cofactor Genomics, Jarret was faculty in the Department of Genetics at Washington University and part of The Genome Institute. While at WashU, he was involved in the Human Genome Project, published the first Cancer Genome, lead the Institute’s Computational Biology Group, and was part of the Institute’s Technology Development Group tasked with characterizing the first RNA-seq experiments on early instruments such as 454 and Illumina/Solexa(Serial #1). Jarret’s work to leverage signals in RNA to propel Precision Medicine Initiatives has been covered by Genetic Engineering News (GEN), Tech Crunch, STAT News, and Wired Magazine. He is a member of the Personalized Medicine Coalition, International Society for Computational Biology, American Association for Cancer Research and is a Y Combinator Alum.
Talk
AI-Derived RNA Profiles Predict Immunotherapy Treatment Response
RNA sequencing and AI-driven Health Expression Models (HEMs) decode the tumor immune microenvironment to characterize cell types, disease state, and treatment response. This predictive immunotherapy diagnostic platform has achieved Medicare coverage and demonstrated 300–400% improvement in accurately predicting patient benefit versus current standard-of-care biomarkers.
AI and Data Sciences Showcase:
Cofactor Genomics
Cofactor Genomics is a commercial-stage precision diagnostics company transforming healthcare by decoding RNA with AI-driven Health Expression Models to characterize disease and predict therapy response. Through its clinically validated, Medicare-approved platform, Cofactor is redefining how immunotherapy decisions are made nationwide.
Session Abstract – PMWC 2026 Silicon Valley
The PMWC 2026 AI Company Showcase will provide a 15-30 minute time slot for selected AI companies to present their latest technologies to an audience of leading investors, potential clients, and partners. We will hear from companies building technologies that expedite the pre-clinical and clinical drug discovery and development process, accelerate patient diagnosis and treatment, or develop scalable systems framework to make AI and deep/machine learning a reality.
